281 related articles for article (PubMed ID: 26847057)
1. Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
Von Hoff DD; Mita MM; Ramanathan RK; Weiss GJ; Mita AC; LoRusso PM; Burris HA; Hart LL; Low SC; Parsons DM; Zale SE; Summa JM; Youssoufian H; Sachdev JC
Clin Cancer Res; 2016 Jul; 22(13):3157-63. PubMed ID: 26847057
[TBL] [Abstract][Full Text] [Related]
2. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
3. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
10. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Nadella P; Shapiro C; Otterson GA; Hauger M; Erdal S; Kraut E; Clinton S; Shah M; Stanek M; Monk P; Villalona-Calero MA
J Clin Oncol; 2002 Jun; 20(11):2616-23. PubMed ID: 12039922
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
[TBL] [Abstract][Full Text] [Related]
12. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.
Tomlinson BK; Thomson JA; Bomalaski JS; Diaz M; Akande T; Mahaffey N; Li T; Dutia MP; Kelly K; Gong IY; Semrad T; Gandara DR; Pan CX; Lara PN
Clin Cancer Res; 2015 Jun; 21(11):2480-6. PubMed ID: 25739672
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
Galsky MD; Eisenberger M; Moore-Cooper S; Kelly WK; Slovin SF; DeLaCruz A; Lee Y; Webb IJ; Scher HI
J Clin Oncol; 2008 May; 26(13):2147-54. PubMed ID: 18362364
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
Garcia AA; Pujari M; Jeffers S; Iqbal S; Lenz HJ; Beringer P; Louie S
Cancer Chemother Pharmacol; 2005 Jul; 56(1):75-82. PubMed ID: 15809878
[TBL] [Abstract][Full Text] [Related]
15. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
Milowsky MI; Nanus DM; Kostakoglu L; Sheehan CE; Vallabhajosula S; Goldsmith SJ; Ross JS; Bander NH
J Clin Oncol; 2007 Feb; 25(5):540-7. PubMed ID: 17290063
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Dy GK; Mandrekar S; Peethambaram PP; Okuno SH; Croghan GC; Hanson LJ; Furth A; Adjei AA
Cancer Chemother Pharmacol; 2005 Dec; 56(6):623-8. PubMed ID: 15999272
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Dreicer R; Petrylak D; Agus D; Webb I; Roth B
Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
Baz W; Nakhl F; El-Soueidi R; Forte F; Lowry J; Aoun N; Burton J
Anticancer Drugs; 2009 Jul; 20(6):508-12. PubMed ID: 19318913
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
